Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 6, 2024
Distillery Therapeutics
Extracellular vesicle delivery of myelin-derived self-peptides for CNS autoimmune diseases
BioCentury | Aug 2, 2024
Distillery Therapeutics
Inhibiting non-canonical STING activity in neurons for MS
BioCentury | Dec 2, 2020
Distillery Therapeutics
Oligodendrocyte-derived extracellular vesicles for multiple sclerosis
DISEASE CATEGORY: Autoimmune disease
INDICATION: Multiple sclerosis (MS) Extracellular vesicles derived from oligodendrocytes could prevent and treat MS. The vesicles were collected from the
INDICATION: Multiple sclerosis (MS) Extracellular vesicles derived from oligodendrocytes could prevent and treat MS. The vesicles were collected from the
BioCentury | Oct 14, 2019
Financial News
Mogrify raises $16M, outlines plans to advance cell therapy platform
BioCentury | Sep 19, 2019
Product Development
Anokion puts liver to the test
Anokion’s preclinical data showcase induction of immune tolerance via liver-targeted autoantigens
BioCentury | Jan 25, 2019
Product R&D
Rubius turns immunotherapy red
Why Rubius is gearing its RBC therapies to mimic immune cell interactions
BioCentury | Dec 11, 2018
Translation in Brief
Diseased oligodendrocytes
Why oligodendrocytes could be new disease targets, not passive victims, in MS
Items per page:
1 - 10 of 40